Core Viewpoint - Hanbang Technology announced a credit impairment loss and asset impairment loss totaling 21.3281 million yuan for the first half of 2025, which will impact the company's consolidated profit by the same amount. This decision is based on prudence and reflects the actual situation of the company's assets without harming the interests of the company and its shareholders [1][1][1] Company Summary - For the first half of 2025, Hanbang Technology's revenue composition is as follows: small molecule drug separation and purification equipment accounts for 70.99%, large molecule drug separation and purification equipment accounts for 22.94%, and others account for 6.07% [1][1][1] - As of the report date, Hanbang Technology has a market capitalization of 4.8 billion yuan [1][1][1] Industry Summary - The pet industry is experiencing a significant boom, with a market size of 300 billion yuan, leading to a surge in stock prices for related listed companies [1][1][1]
汉邦科技：2025年半年度计提信用减值损失及资产减值损失共计2132.81万元